---
input_text: 'Umbilical Cord Blood Transplantation for Fanconi Anemia with a special
  focus on late complications: a Study on Behalf of Eurocord and SAAWP-EBMT. BACKGROUND:
  Hematopoietic cell transplant (HCT) remains the only available curative treatment
  for Fanconi Anemia (FA), with particularly favorable outcomes reported after matched
  sibling donor (MSD) transplant. OBJECTIVES: To describe outcomes, with a special
  focus on late complications, in FA patients who underwent umbilical cord blood transplantation
  (UCBT). STUDY DESIGN: Retrospective analysis of allogeneic UCBT for FA performed
  between 1988 and 2021 in European Society for Blood and Marrow Transplantation (EBMT)
  affiliated centers. RESULTS: A total of 205 FA patients underwent UCBT (55 related
  and 150 unrelated) across 77 transplant centers. Indications for UCBT were bone
  marrow failure in 190 patients and acute leukemia/myelodysplasia in 15 patients.
  Median age at transplant was 9 (1.2-43) years, with only 20 patients over the age
  of 18. Among the donor-recipient pairs, 56% (n=116) had 0-1/6 HLA mismatch. Limited
  field radiotherapy was administered to 28% (n=58) and 78% (n=160) received a Fludarabine
  (FLU)-based conditioning regimen. Serotherapy consisted of anti-thymocyte globulin
  (ATG, n=159; 78%) or alemtuzumab (n=12; 6%). Median follow-up was 10 years for related
  and 7 years for unrelated UCBT. Excellent outcomes were observed in the setting
  of related UCBT, including a 60-day cumulative incidence (CI) of neutrophil recovery
  at 98.1% (93.9-100), a 100-day CI of grades II-IV acute graft-versus-host disease
  (GVHD) at 17.3% (9.5-31.6), and a 5-year CI of chronic GVHD at 22.7% (13.3-38.7;
  13% extensive). Five-year overall survival (OS) was 88%. In multivariate analysis,
  none of the factors included in the model predicted a better OS. In unrelated UCBT,
  the 60-day CI of neutrophil recovery was 78.7% (71.9-86.3), the 100-day CI of grade
  II-IV aGVHD was 31.4% (24.6-40.2) and the 5-year CI of cGVHD was 24.3% (17.8-32.2)
  (12% extensive). Five-year OS was 44%. In multivariate analysis, negative recipient
  CMV serology, FLU-based conditioning, age at UCBT less than 9 years and 0-1/6 HLA
  mismatch were associated with improved OS. A total of 106 patients, including 5
  AL/MDS, survived for over 2 years after UCBT. Nine of these patients developed subsequent
  neoplasms (SN), including one donor-derived AML and 8 solid tumors, at a median
  of 9.7 (2.3-21.8) years post-UCBT (one related and 8 unrelated UCBT). In a subset
  of 49 patients with available data, late non-malignant complications affecting various
  organ systems were observed at a median of 8.7 (2.7-28.8) years post-UCBT. CONCLUSION:
  UCB is a valid source of stem cells for transplantation in patients with FA, with
  best results observed after related UCBT. After unrelated UCBT, improved survival
  was observed in patients transplanted at a younger age, with FLU-based conditioning
  and better HLA parity. The incidence of organ specific complications and subsequent
  neoplasms was relatively low. Subsequent neoplasm incidence, mostly squamous cell
  carcinoma, increases with time. Rigorous follow-up and life-long screening is crucial
  in Fanconi anemia patients transplant survivors. The long-term complications observed
  emphasize the need for long-life screening of transplant survivors.'
raw_completion_output: |-
  primary_disease: Fanconi Anemia

  medical_actions: Umbilical cord blood transplantation (UCBT); Hematopoietic cell transplant (HCT); Limited field radiotherapy; FLU-based conditioning regimen; Administration of anti-thymocyte globulin (ATG); Administration of alemtuzumab; Multivariate analysis; Rigorous follow-up; Life-long screening

  symptoms: Bone marrow failure; Acute leukemia; Myelodysplasia

  chemicals: Fludarabine (FLU); Anti-thymocyte globulin (ATG); Alemtuzumab

  action_annotation_relationships: Umbilical cord blood transplantation (UCBT) TREATS bone marrow failure IN Fanconi Anemia; Hematopoietic cell transplant (HCT) TREATS bone marrow failure IN Fanconi Anemia; UCBT TREATS acute leukemia IN Fanconi Anemia; UCBT TREATS myelodysplasia IN Fanconi Anemia; FLU-based conditioning regimen (with Fludarabine) PREVENTS graft-versus-host disease IN Fanconi Anemia; Administration of anti-thymocyte globulin (ATG) PREVENTS graft-versus-host disease IN Fanconi Anemia; Administration of alemtuzumab PREVENTS graft-versus-host disease IN Fanconi Anemia; Life-long screening PREVENTS subsequent neoplasms IN Fanconi Anemia
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Life-long screening PREVENTS subsequent neoplasms IN Fanconi Anemia

  ===

extracted_object:
  primary_disease: MONDO:0019391
  medical_actions:
    - MAXO:0010033
    - MAXO:0000149
    - Limited field radiotherapy
    - FLU-based conditioning regimen
    - Administration of anti-thymocyte globulin (ATG)
    - Administration of alemtuzumab
    - Multivariate analysis
    - Rigorous follow-up
    - Life-long screening
  symptoms:
    - HP:0005528
    - HP:0002488
    - HP:0002863
  chemicals:
    - Fludarabine (FLU)
    - Anti-thymocyte globulin (ATG)
    - Alemtuzumab
  action_annotation_relationships:
    - subject: <Umbilical cord blood transplantation>
      predicate: <TREATS>
      object: <bone marrow failure>
      qualifier: <Fanconi Anemia>
      subject_extension: <Umbilical cord blood>
    - subject: <Hematopoietic cell transplant>
      predicate: <TREATS>
      object: <bone marrow failure>
      qualifier: <Fanconi Anemia>
      subject_extension: <Hematopoietic cell transplant>
    - subject: MAXO:0010033
      predicate: TREATS
      object: HP:0002488
      qualifier: MONDO:0019391
    - subject: MAXO:0010033
      predicate: TREATS
      object: HP:0002863
      qualifier: MONDO:0019391
    - subject: FLU-based conditioning regimen
      predicate: PREVENTS
      object: graft-versus-host disease
      qualifier: MONDO:0019391
      subject_qualifier: with Fludarabine
      subject_extension: Fludarabine
    - subject: Administration
      predicate: PREVENTS
      object: graft-versus-host disease
      qualifier: MONDO:0019391
      subject_extension: anti-thymocyte globulin
    - subject: Administration of alemtuzumab
      predicate: PREVENTS
      object: graft-versus-host disease
      qualifier: MONDO:0019391
      subject_extension: alemtuzumab
    - subject: Life-long screening
      predicate: PREVENTS
      object: subsequent neoplasms
      qualifier: MONDO:0019391
named_entities:
  - id: MONDO:0019391
    label: Fanconi anemia
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation (HSCT)
  - id: CHEBI:18198
    label: ADCs
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: CHEBI:38215
    label: Calcium channel blocker
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8069
    label: Phenobarbital
  - id: CHEBI:2668
    label: Amlodipine
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000016
    label: Cellular therapy
  - id: HP:0001871
    label: Blood dyscrasias
  - id: MAXO:0000595
    label: Radiography
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0034057
    label: Congenital defects
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005233
    label: Non-small cell lung cancer (NSCLC)
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0002863
    label: Myelodysplasia
  - id: HP:0001909
    label: Leukemia
  - id: MONDO:0016624
    label: Hereditary anemia
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0005570
    label: Hematological disorders
  - id: HP:0002664
    label: cancer
  - id: MONDO:0015253
    label: Diamond Blackfan anemia
  - id: MAXO:0000600
    label: Kidney replacement therapy (KRT)
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003259
    label: Elevated serum creatinine (SCr > 100micromol/l)
  - id: MONDO:0001529
    label: Bone marrow failure (BMF)
  - id: HP:0002860
    label: oral squamous cell carcinoma (SCC)
  - id: MONDO:0100339
    label: Fanconi anemia (FA)
  - id: CHEBI:28680
    label: Ara-C
  - id: CHEBI:27899
    label: Cisplatin
  - id: HP:0011793
    label: Malignant tumors
  - id: HP:0000818
    label: Endocrinopathies
  - id: HP:0002745
    label: Oral leukoplakia
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:231614
    label: Nivolumab
  - id: CHEBI:25016
    label: PBS
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:229764
    label: Selinexor
  - id: CHEBI:229762
    label: Eltanexor
  - id: HP:0006775
    label: Multiple Myeloma
  - id: CHEBI:229763
    label: exportin 1 inhibitors
  - id: MONDO:0015909
    label: aplastic anemia
  - id: HP:0004808
    label: Acute myeloid leukaemia
  - id: MAXO:0000004
    label: Surgery
  - id: MAXO:0000014
    label: Radiotherapy
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001945
    label: Fever
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome (PRES)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0001188
    label: Laparoscopy
  - id: HP:0000988
    label: Skin rash
  - id: MONDO:0010161
    label: Tyrosinemia Type 1
  - id: HP:0001919
    label: acute kidney injury (AKI)
  - id: HP:0000822
    label: hypertension
  - id: MAXO:0001298
    label: therapy
  - id: HP:0040012
    label: Increased chromosomal breakage
  - id: MONDO:0004631
    label: Tongue cancer (TC)
  - id: CHEBI:4735
    label: EDTA
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0025085
    label: Blood in stool
  - id: HP:0000568
    label: Microphthalmia
  - id: HP:0000482
    label: microcornea
  - id: HP:0000508
    label: ptosis
  - id: HP:0011496
    label: limbal neovascularization
  - id: HP:0001097
    label: keratoconjunctivitis sicca
  - id: CHEBI:62932
    label: Mycophenolate
  - id: MONDO:0008903
    label: Lung Cancer
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0032169
    label: severe infections
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: MONDO:0005109
    label: HIV
  - id: HP:0001622
    label: Preterm delivery
  - id: HP:0100601
    label: Eclampsia
  - id: MONDO:0043455
    label: Hereditary hematological malignancy (HHM)
  - id: MONDO:0043797
    label: Spinal Cord Injury (SCI)
  - id: CHEBI:27306
    label: Vitamin B6
  - id: HP:0001915
    label: aplastic anemia
  - id: MONDO:0001056
    label: Gastric cancer
  - id: MAXO:0001193
    label: Esophagogastroduodenoscopy
  - id: CHEBI:31941
    label: Oxaliplatin
  - id: HP:0012126
    label: Gastric cancer
  - id: MONDO:0005575
    label: Colorectal Cancer
  - id: CHEBI:46345
    label: 5-fluorouracil (5-FU)
  - id: CHEBI:15640
    label: Folinic acid
  - id: HP:0008209
    label: Premature ovarian insufficiency (POI)
  - id: HP:0000026
    label: Testicular failure
  - id: CHEBI:81569
    label: Follicle-stimulating hormone (FSH)
  - id: CHEBI:74539
    label: Luteinizing hormone (LH)
  - id: MONDO:0010651
    label: myelodysplastic syndromes (MDS)
  - id: MAXO:0000079
    label: genetic counseling
  - id: MONDO:0018881
    label: myelodysplastic syndromes
  - id: MAXO:0010033
    label: cord blood transplantation
  - id: CHEBI:50443
    label: hematopoietic stem cells (HSC)
  - id: MONDO:0000159
    label: Bone marrow failure syndromes
  - id: HP:0001903
    label: Anemia
  - id: MONDO:0007959
    label: Medulloblastoma (MB)
  - id: HP:0002885
    label: Medulloblastoma
  - id: CHEBI:3498
    label: CTX
  - id: HP:0000815
    label: Hypergonadotropic hypogonadism
  - id: HP:0000044
    label: Hypogonadotropic hypogonadism
  - id: HP:0008223
    label: Subclinical hypothyroidism
  - id: HP:0011787
    label: Central hypothyroidism
  - id: HP:0000855
    label: Insulin resistance
  - id: HP:0003119
    label: Dyslipidemia
  - id: HP:0002671
    label: Basal cell cancer
  - id: CHEBI:7421
    label: N-acetylcysteine (NAC)
  - id: CHEBI:66919
    label: ruxolitinib
  - id: MAXO:0000757
    label: infusion
  - id: CHEBI:35341
    label: steroids
  - id: MONDO:0011996
    label: Chronic Myeloid Leukemia (CML)
  - id: MAXO:0009004
    label: Whole exome sequencing
  - id: CHEBI:83766
    label: Olaparib
  - id: CHEBI:38637
    label: Tyrosine Kinase Inhibitors (TKIs)
  - id: HP:0002488
    label: Acute leukemia
